GlassScriptBiofire Respiratory Panel 2.1
Payments companies reported to CMS as associated with Biofire Respiratory Panel 2.1. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Biofire Respiratory Panel 2.1, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Biofire Respiratory Panel 2.1
These are the largest totals companies reported as associated with Biofire Respiratory Panel 2.1. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Kenneth Alexander | Orlando, FL | Infectious Disease | $11,377.50 |
| Larissa May | Washington, DC | Emergency Medicine | $7,901.13 |
| Daniel Feinstein | Pinehurst, NC | Critical Care Medicine (Internal Medicine) | $7,885.24 |
| Christopher Polage | Sacramento, CA | $7,437.19 | |
| David Talan | Iowa City, IA | Emergency Medicine | $7,018.90 |
| Andrew Meltzer | Washington, DC | Emergency Medicine | $6,665.43 |
| Lilian Abbo | Miami, FL | Infectious Disease | $6,654.34 |
| Sameer Desai | Lexington, KY | Emergency Medicine | $6,171.39 |
| Sonali Advani | Durham, NC | Infectious Disease | $6,071.37 |
| Ann Stapleton | Palm Springs, CA | Infectious Disease | $5,910.15 |
Prescribed Biofire Respiratory Panel 2.1?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.